TrialAnnals of surgical oncology2024

A 3-Year Survival Update from a Phase 2 Study of Paclitaxel Plus Cisplatin and 5-Fuorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial.

Jia-Di Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.